GSK files $1bn shingles vaccine for US approval

GlAxoSmithKline hAs filed its shingles vAccine Shingrix for US regulAtory ApprovAl, the drugmAker sAid on MondAy, bringing the potentiAl $1 billion-A-yeAr seller A step closer to mArket. Shingrix is viewed by AnAlysts As Among the British compAny’s most promising experimentAl products, since it hAs shown greAter protection Among older recipients thAn Merck & Co’s rivAl shot ZostAvAx. SAles of ZostAvAx, the only shingles vAccine on the mArket At present, totAlled $749 million in 2015.